The effect of an mGluR5 inhibitor on procedural memory and avoidance discrimination impairments in Fmr1 KO mice
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Fragile X syndrome (FXS) is the most common inherited form of intellectual disability. Patients with FXS do not only suffer from cognitive problems, but also from abnormalities/deficits in procedural memory formation. It has been proposed that a lack of fragile X mental retardation protein (FMRP) leads to altered long‐term plasticity by deregulation of various translational processes at the synapses, and that part of these impairments might be rescued by the inhibition of type I metabotropic glutamate receptors (mGluRs). We recently developed the Erasmus Ladder, which allows us to test, without any invasive approaches, simultaneously, both procedural memory formation and avoidance behavior during unperturbed and perturbed locomotion in mice. Here, we investigated the impact of a potent and selective mGluR5 inhibitor (Fenobam) on the behavior of Fmr1 KO mice during the Erasmus Ladder task. Fmr1 KO mice showed deficits in associative motor learning as well as avoidance behavior, both of which were rescued by intraperitoneal administration of Fenobam. While the Fmr1 KO mice did benefit from the treatment, control littermates suffered from a significant negative side effect in that their motor learning skills, but not their avoidance behavior, were significantly affected. On the basis of these studies in the FXS animal model, it may be worthwhile to investigate the effects of mGluR inhibitors on both the cognitive functions and procedural skills in FXS patients. However, the use of mGluR inhibitors appears to be strongly contraindicated in healthy controls or non‐FXS patients with intellectual disability.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481 · cited 1×
“…28 December 2011 Fragile X syndrome (FXS) is the most common genetic form of mental impairment (WHO 1996), affecting approximately 1 in 4000 males (Crawford et al. 2002; de Vries et al. 1997; Patsalis et al. 1999; Youings et al. 2000) and 1 in 6000 females worldwide (Crawford et al. 2001).”
BackgroundSelf-citationThe mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 1×
“Accordingly, the ‘mGluR theory of FXS’ suggests that the neurobiological and psychiatric symptoms of FXS result from an exaggerated AMPA receptor internalization triggered by mGluR activation (Bear et al. 2004).”
BackgroundInstability of a 550-Base Pair DNA Segment and Abnormal Methylation in Fragile X Syndrome
Oberlé, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., Boué, J., Bertheas, M. F., & Mandel, J. L. (1991) · Science · doi:10.1126/science.252.5009.1097 · Cited by 1,499
FMR1 and the fragile X syndrome: Human genome epidemiology review
Crawford, D. C., Acuña, J. M., & Sherman, S. L. (2001) · Genetics in Medicine · doi:10.1097/00125817-200109000-00006 · Cited by 711 · cited 1×
“…28 December 2011 Fragile X syndrome (FXS) is the most common genetic form of mental impairment (WHO 1996), affecting approximately 1 in 4000 males (Crawford et al. 2002; de Vries et al. 1997; Patsalis et al. 1999; Youings et al. 2000) and 1 in 6000 females worldwide (Crawford et al. 2001).”
BackgroundWeiler, I. J., Irwin, S. A., Klintsova, A. Y., Spencer, C. M., Brazelton, A. D., Miyashiro, K., Comery, T. A., Patel, B., Eberwine, J., & Greenough, W. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5395 · Cited by 644 · cited 2×
“2003), is present in the postsynaptic compartment and locally synthesized upon mGluR activation (Weiler et al. 1997).”
BackgroundA pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · cited 3×
“These results agree with the reports that showed positive effects of mGluR5 inhibitors on abnormalities in prepulse inhibition (PPI) in FXS patients (Berry-Kravis et al. 2009) and Fmr1 KO mice (de Vrij et al. 2008).”
BackgroundResultFragile X mice develop sensory hyperreactivity to auditory stimuli
Chen, L., & Toth, M. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00036-7 · Cited by 345
Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice
de Vrij, F. M. S., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., & Willemsen, R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.04.002 · Cited by 313 · cited 1×
“These results agree with the reports that showed positive effects of mGluR5 inhibitors on abnormalities in prepulse inhibition (PPI) in FXS patients (Berry-Kravis et al. 2009) and Fmr1 KO mice (de Vrij et al. 2008).”
ResultSelf-citationPorter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089839 · Cited by 308 · cited 3×
“…dazole-2-yl)urea], which is a clinically validated non-benzodiazepine anxiolytic drug, is a selective and potent mGluR5 receptor antagonist acting at an allosteric modulatory site shared with 2-methyl-6(phenylethynyl)-pyridine (MPEP) (Porter et al. 2005).”
BackgroundInfluentialDissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome.
Liu, Z.-H., & Smith, C. B. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.02.066 · Cited by 112 · cited 1×
“This possibility is in line with other FXS mouse model studies in which a general lower level of anxiety and/or general deficits in fear memory formation were observed (Liu & Smith 2009).”
ResultReversal of sensorimotor gating abnormalities in Fmr1 knockout mice carrying a human Fmr1 transgene.
Paylor, R., Yuva-Paylor, L. A., Nelson, D. L., & Spencer, C. M. (2008) · Behavioral Neuroscience · doi:10.1037/a0013047 · Cited by 46 · cited 2×
“Moreover, different from other tests such as eyeblink conditioning, in which Fmr1 KO mice also show a phenotype (Chen & Toth 2001; Paylor et al. 2008; Spencer et al. 2006), the Erasmus Ladder test does not require any surgical intervention and allows drug screening at an automated, medium-throughput level.”
Background
Cited by
The Pathophysiology of Fragile X (and What It Teaches Us about Synapses)
Bhakar, A. L., Dölen, G., & Bear, M. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153138 · Cited by 370
An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
Sepulveda-Falla, D., Barrera-Ocampo, A., Hagel, C., Korwitz, A., Vinueza-Veloz, M. F., Zhou, K., Schonewille, M., Zhou, H., Velazquez-Perez, L., Rodriguez-Labrada, R., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66407 · Cited by 135
Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back
Gross, C., Hoffmann, A., Bassell, G. J., & Berry-Kravis, E. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0355-9 · Cited by 105
Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice
Gantois, I., Pop, A. S., de Esch, C. E. F., Buijsen, R. A. M., Pooters, T., Gomez-Mancilla, B., Gasparini, F., Oostra, B. A., D’Hooge, R., & Willemsen, R. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.10.059 · Cited by 100
Self-citation
Metadata
- Authors
- Vinueza Veloz, M. F., Buijsen, R. A. M., Willemsen, R., Cupido, A., Bosman, L. W. J., Koekkoek, S. K. E., Potters, J. W., Oostra, B. A., & De Zeeuw, C. I.
- Venue
- Genes, Brain and Behavior
- Publisher
- Wiley
- Published
- 2012-01-19
- Volume
- 11
- Issue
- 3
- Pages
- 325-331
- ISSN
- 1601-183X (ISSN-L)
- 1601-1848
- OpenAlex
- W2001996712
- Cited by
- 65
- References
- 11
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.